This session discusses what we know about long COVID, including long-term effects, wide range of symptoms, the role of vaccinations, and individuals at increased risk for long-term health problems.

Bladder cancer (BC) is the tenth most common cancer worldwide, and its associated five-year survival rate declines rapidly (from 96% to 6%) as it progresses from in situ through local invasion, regional spread and finally to distal spread. Thus, early detection and timely therapeutic interventions are crucial to improve outcomes and reduce the burden of disease. Outcomes have been further improved by the integration of recently approved therapies for BC, the utilization of biomarkers to guide treatment plans and the opportunity for eligible patients with BC to enroll in clinical trials. For all treatment plans, effective communication among the health care team is crucial for providing comprehensive care for this condition. This activity will provide participants with an overview of early BC diagnosis and its impact on survival rates. It will explore recently approved therapies for BC both as standalone treatments and in combination with established therapeutic approaches. Emerging therapies and their potential benefits will be examined, and the value of biomarkers will be discussed. Participants will gain insight into treatment strategies to optimize patient outcomes in BC.

This session examines the experiences and perspective of a transplant surgeon describing his personal journey as a transplant recipient.

Despite the large increase in the number of multi-organ transplants (MOTs) performed over the past few years, challenges still exist in this arena. Among these unresolved issues are a lack of standardized MOT eligibility criteria across institutions, regions and different organ combinations. Ethical issues have also arisen regarding equity in organ allocation amidst a limited organ supply, as many MOT candidates get priority allocation for nonprimary organs versus individuals requiring that organ as a single transplant; this prioritization may impact optimal recipient and graft survival as well. In this session, learn more about multi-organ allocation and its accompanying challenges, risks, benefits, and expected outcomes, as well as the limitations of MOT for potential recipients.